Trial intelligence / Profile preview

TPI 287 in Metastatic Prostate Cancer

NCT00479635Phase 2

Key facts

Status: Terminated
Start: Jan 2007
Primary completion: Aug 2008
Countries: 1
Sponsor: Cortice Biosciences Inc.
Modality: Small Molecules

Drugs: abeotaxane
Conditions: prostate cancer (PCa)

Overview

Phase 2, open-label trial of abeotaxane in prostate cancer (PCa) (2 arms), sponsored by Cortice Biosciences Inc. Primary endpoint: Response Rate at 15 months. Started Jan 2007; status: terminated.

Design

2 arms

Study design: Non-randomizedOpen-label

Taxane Sensitive
Patients with >3 months exposure to prior taxane before progression
Taxane Resistant
Patients with <=3 months exposure to prior taxane before progression

Endpoints

Primary

Response Rate15 months

Secondary

Time to Progression15 months
Duration of Response6 months
Safety

Beyond the preview

Go deeper on NCT00479635.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00479635.